Pylarify (piflufolastat F18)
Ended Awarded Last action
- Contract number
- 36C26022F0369
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $169,623
Award facts
- Contract value 51% obligated
- $332,280.71 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- New York, NY 10007, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $3,609 | |
| Supplemental Agreement for work within scope | -$83,292 | |
| Supplemental Agreement for work within scope | $166,014 | |
| Original award | $245,950 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $332,280.71 by Veterans Integrated Service Network 20 (VISN 20) on July 5, 2022, for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection. This is a firm fixed-price contract with no set-aside designation and an ultimate completion date of July 4, 2023. The delivery order was issued against the company's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract, which enables the Veterans Health Administration to efficiently procure critical radiopharmaceutical products across multiple medical facilities. The contract specifies performance at the company's facility in New York, NY, though manufacturing and distribution typically occur at the company's primary location in North Billerica, Massachusetts.
This delivery order represents one component of Progenics Pharmaceuticals' substantial federal contracting portfolio with the Department of Veterans Affairs, which has awarded the company over 150 individual contract awards across multiple Veterans Integrated Service Networks and other federal healthcare agencies including the Defense Health Agency and National Institutes of Health. The company maintains multiple blanket purchase agreements and indefinite delivery vehicles valued up to $290 million for ongoing radiopharmaceutical procurement, with performance periods extending through 2030. As the primary supplier of PYLARIFY to the federal government, Progenics supports critical diagnostic imaging programs that serve veterans and military personnel across the federal healthcare system.
Quick answers
Who was awarded contract 36C26022F0369?
36C26022F0369 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on July 5, 2022.
How much is contract 36C26022F0369 worth?
The government has obligated $169,623 on 36C26022F0369. Its current value, with exercised options, is $332,281.
Is contract 36C26022F0369 an order under another contract?
Yes. 36C26022F0369 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26022F0369 competed?
The extent of competition for 36C26022F0369 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award